# Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

> **NCT06999707** · PHASE2 · RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 45 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma
- Tremelimumab
- Durvalumab
- Radiotherapy

## Interventions

- **RADIATION:** Photon radiotherapy
- **DRUG:** Tremelimumab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06999707
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2030-05-31
- **Final completion:** 2033-05-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06999707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06999707, "Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06999707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*